TM
PTCT icon

Torren Management’s PTC Therapeutics PTCT Stock Holding History

Torren Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$653 Hold
8
– – ﹤0.01% 825
2026
Q1 		$545 Hold
8
– – ﹤0.01% 867
2025
Q4 		$608 Buy
+8
New +$581 ﹤0.01% 1298

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Universal-Beteiligungs- und Servicegesellschaft
Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Torren Management's PTCT Position: Q2 2026 in Review

Torren Management held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 8 shares worth $653. The position accounts for ﹤0.01% of the portfolio, ranked #825.

Torren Management first reported a position in PTCT in Q4 2025 and has held it in 3 quarters since. 152 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Torren Management held 8 shares of PTC Therapeutics worth $653 as of Q2 2026.
  • Torren Management left its PTC Therapeutics share count unchanged in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of Torren Management's portfolio in Q2 2026, its #825 holding.
  • Torren Management first reported a position in PTC Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 152 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Torren Management's 13F filing for Q2 2026, filed 10 Jul 2026.